Skip to main
XOMA
XOMA logo

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is projected to experience significant revenue growth, with a forecasted increase of over 20% annually through 2026, driven by commercial sales ramps and new product launches. The company's revenue rose dramatically from $4.8 million in 2023 to $28.5 million in 2024, thanks to enhanced income from purchased receivables and customer contracts. Looking forward, XOMA anticipates generating $49.0 million in revenue by 2026, along with a net income of $2.4 million, bolstered by the contributions of earlier-stage assets and possible milestone payments.

Bears say

XOMA Royalty Corp has experienced revenue and net earnings variability largely due to the unpredictable nature of the international biotechnology market and external economic factors, which could adversely affect the company's operations and demand for its services. The potential for failed clinical trials and challenges in securing adequate funding for drug development presents critical risks that may hinder the company’s growth prospects and stock performance. Additionally, the departure of key executives with extensive industry knowledge could create operational challenges and undermine investor confidence in XOMA's future potential.

XOMA (XOMA) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 2 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.